Clinical data of fluocortin butylester (FCB) - a new inhalable corticoid.
A report was given on a new inhalable corticoid - Fluocortin butylester (FCB) - administered to patients with bronchial asthma. Forty eight cases with extrinsic asthma induced by allergen challenge participated in this study. A good protective effect was seen in 10 patients inhaling 8 mg daily. This dosis produced a remarkable effect of Raw and FRC. No side effects were observed in a study carried over 3 years. Furthermore, there was detected a normal adrenal function during the duration of FCB therapy.